Monitor for future prospectus supplements or 8-K filings indicating an actual drawdown under the shelf or ATM program, which could lead to near-term stock dilution. The $81M market cap makes even modest issuances potentially impactful.
PLRX drugs
PLRX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 7 $1.31entry
- T+1 · 7mo ago +3.82%α +1.28% · $1.36
- T+5 · 7mo ago −0.76%α −6.09% · $1.30
- T+20 · 7mo ago −9.16%α −18.94% · $1.19
- T+60 · 5mo ago −10.69%α −23.96% · $1.17
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pliant Therapeutics' $300 million shelf registration, including a $50 million at-the-market (ATM) offering program, has become effective. The company can now sell securities from time to time over the next three years, creating potential for future dilution.
Key Facts
- Shelf registration (Form S-3) has become effective, allowing Pliant Therapeutics to raise up to $300 million in capital over the next three years.
- Of the $300 million, $50 million is designated for an at-the-market (ATM) offering program with Leerink Partners LLC.
- Securities offered may include common stock, preferred stock, debt, units, and warrants, with specific terms disclosed in future prospectus supplements.
- The effectiveness allows the company to access capital markets opportunistically, but no immediate offering has been announced.
Financial Impact
Up to $300,000,000 in potential future dilution, with $50,000,000 available immediately under the ATM program
Risk Factors
- Future equity issuances could dilute existing shareholders
- ATM program may be used during periods of low stock price, exacerbating downside pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| EFFECT Filing (Primary) | 9999999995-26-001103 |
| Document: 9999999995-26-001103-index.html | 9999999995-26-001103 |
| Document: 9999999995-26-001103.txt | 9999999995-26-001103 |
Track record
8 reports on PLRX
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +11.02% at T+60 after the May 11, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.6970 Now $0.6930 −0.57% settles Feb 11
- Aug 18, 202612w ago Press Release Bullish 4/10 Entry $1.15 to $0.7857 Now $0.6930 −39.74% ▼ −31.68% −29.64% vs SPY
- May 11, 202627w ago 8-K Neutral 4/10 No price data
- May 11, 202627w ago Press Release Bearish 6/10 Entry $1.18 to $1.05 Now $0.6930 +41.27% ▲ +11.02% +15.40% vs SPY
- Apr 17, 202630w ago 8-K Mixed 6/10 Entry $1.29 to $1.12 Now $0.6930 −46.28% ▼ −13.18% −19.96% vs SPY
- Apr 7, 202632w ago EFFECT Neutral 4/10 Viewing Entry $1.31 to $1.17 Now $0.6930 −47.10% ▼ −10.69% −23.96% vs SPY
- Mar 11, 202635w ago 8-K Bullish 7/10 Entry $1.41 to $1.15 Now $0.6930 −50.85% ▼ −18.44% −29.14% vs SPY
- Mar 3, 202636w ago 8-K Neutral 3/10 Entry $1.29 to $1.25 Now $0.6930 −46.28% ▼ −3.10% −13.19% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers